Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest hopes the SNRI can follow the enantiomer blockbuster model. The application includes in vitro data showing that levomilnacipran has a greater potency for norepinephrine reuptake inhibition, without directly affecting the uptake of dopamine or other neurotransmitters.

You may also be interested in...



Additional Cariprazine Trial Could Put Forest In A Better Competitive Position

FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.

Additional Cariprazine Trial Could Put Forest In A Better Competitive Position

FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.

Brintellix Label Gives Lundbeck Ground For Tolerability Claims

Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel